Evidence map›Paper›PMID 33451320›Full record

ArticleCancer cell international2021

Exosomes from tamoxifen-resistant breast cancer cells transmit drug resistance partly by delivering miR-9-5p.

Jianhui Liu, Shaoliang Zhu, Wei Tang, Qinghua Huang, Yan Mei, Huawei Yang

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Cancer cell international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 52 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Extracellular vesicle-mediated chemoresistance in breast cancer: focus on miRNA cargo.Extracellular vesicles and circulating nucleic acids · 2025
    Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. The role and clinical applications of exosomes in cancer drug resistance.Cancer drug resistance (Alhambra, Calif.) · 2024
    Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Jianhui LiuThe First Department of Breast Surgery, Guangxi Medical University Cancer Hospital, Nanning, 530021, People's Republic of China.
Shaoliang ZhuDepartment of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, No.71, Hedi Road, Nanning, 530021, Guangxi, People's Republic of China.
Wei TangThe First Department of Breast Surgery, Guangxi Medical University Cancer Hospital, Nanning, 530021, People's Republic of China.
Qinghua HuangThe First Department of Breast Surgery, Guangxi Medical University Cancer Hospital, Nanning, 530021, People's Republic of China.
Yan MeiThe First Department of Breast Surgery, Guangxi Medical University Cancer Hospital, Nanning, 530021, People's Republic of China.
Huawei YangThe First Department of Breast Surgery, Guangxi Medical University Cancer Hospital, Nanning, 530021, People's Republic of China. lordyhw@163.com.ORCID http://orcid.org/0000-0003-0963-220X
Guangxi Medical University · CN

Funding

Mechanism of Mir-194-5p targeting Wnt/β-catenin pathway regulation SATB1 in breast cancer invasion and metastasis No.2018GXNSFAA138049Mechanism of RSK4-targeted PI3K / AKT Pathway Regulating ACTN4 in Chemotherapy-Resistant Breast Cancer No. 8186100068
6 · The paper itself

Abstract

backgroundResistance to drug therapy is a major impediment for successful treatment of patients suffering from breast cancer (BC). Tamoxifen (TAM) is an extensively used therapeutic agent, which substantially reduces the risk of recurrence and associated mortality in BC. This study demonstrated that exosomal transfer of microRNA-9-5p (miR-9-5p) enhanced the resistance of MCF-7 cells to TAM.

methodsInitially, BC-related differentially expressed genes (DEGs) and their upstream regulatory miRNAs were identified. The TAM-resistant MCF-7 (MCF-7/TAM) cell line and the non-medicated sensitive MCF-7 cell line were formulated, followed by isolation of the exosomes. Next, the apoptosis rate of exosome-treated MCF-7 cells was determined after co-culture with TAM. The interaction between miR-9-5p and ADIPOQ was identified by a combination of bioinformatic analysis and luciferase activity assay. In order to validate the effect of miR-9-5p and ADIPOQ on TAM resistance in the MCF-7 cells in vitro and in vivo, miR-9-5p was delivered into the exosomes. ADIPOQ and miR-9-5p were identified as the BC-related DEG and upstream regulatory miRNA.

resultsExosomes derived from the MCF-7/TAM cells could increase the resistance of MCF-7 cells to TAM. Notably, miR-9-5p altered the sensitivity of BC cells to TAM. In addition, ADIPOQ was negatively regulated by miR-9-5p. Furthermore, MCF-7/TAM cell-derived miR-9-5p inhibited the apoptosis of MCF-7 cells, and promoted the cell resistance to TAM. In vivo experiments in nude mice ascertained that the tumor injected with exosomal miR-9-5p showed improved resistance to TAM.

conclusionsExosomal transfer of miR-9-5p augmented the drug resistance of BC cells to TAM by down-regulating ADIPOQ, suggesting its functionality as a candidate molecular target for the management of BC.

Indexed as

ADIPOQBreast cancerDrug resistanceExosomesMCF-7MCF-7/TAMMicroRNA-9-5pTamoxifen

Identifiers

PMID33451320
PMCPMC7809732
OpenAlexW3124676529

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.